Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

UCLA tests if naltrexone cancels the Fear-Busting power of a hug

NCT ID NCT04166071

Knowledge-focused Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

Researchers at UCLA are studying whether naltrexone, a drug that blocks opioid receptors, can stop reminders of a social support figure from helping people overcome fear. Sixty healthy adults aged 18-35 will receive either naltrexone or a placebo, then undergo a fear extinction procedure where threatening cues are paired with images of a loved one. The goal is to see if the drug disrupts the brain's natural safety-signal mechanism, shedding light on how social bonds protect against fear.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
naltrexone
What this could lead to
If it works, this could reveal how social support helps reduce fear, potentially guiding future treatments for anxiety disorders.
What could go wrong
This is a very early, small study (60 healthy people) testing a single dose. It may not translate to real-world fear or anxiety conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * healthy adults 18 and 35 * fluent in English * no history of mental illness (including anxiety, depression, phobia, or any other mental health related disorder diagnosed by a mental health professional) Exclusion Criteria: * pregnant or planning to become pregnant during the experiment period * presence of chronic mental illness (as determined by the report of a past diagnosis of mental illness by a physician or psychologist and/or the prescription of medication related to mental health disorder; including anxiety, depression, phobia, or any other diagnosed psychological disorder) * chronic physical illness (as determined by past diagnosis and/or treatment by a physician) * history of liver disease or abnormal liver function * current and regular use of prescription medications related to mental health disorders or liver function * previous history of fainting during blood draws * difficulty or discomfort swallowing pills * history of substance abuse or addiction (especially alcohol or opiate abuse) Other exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FEAR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FEAR

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCLA

    Los Angeles, California, 90095, United States

  • UCLA Department of Psychology, 5514 Pritzker Hall

    Los Angeles, California, 90095-1563, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.